State Street SPDR S&P Biotech ETF (XBI) Holdings

이 페이지는 영어 원문에서 AI로 기계 번역되었습니다. 영어 버전이 기준입니다. 영어 버전 읽기

정보 제공만을 목적으로 합니다. 재정적 조언이 아닙니다.

빠른 답변

State Street SPDR S&P Biotech ETF (XBI) has a last stored price of $149.54, as of the Oct 23, 2026 trading session. It has a 0.35% expense ratio and $7.8B in assets under management.

Holdings and weights below are as of Mar 15, 2026. In the stored portfolio snapshot, the largest listed holding is Moderna Inc (MRNA) at 2.25%, and the largest sector allocation is Healthcare at 100.0%.

State Street SPDR S&P Biotech ETF (XBI) ETF — Price, Holdings & Analysis

ETF 개요

XBI aims to capture the performance of the biotechnology sector within the broader equity market. It tracks the S&P Biotechnology Select Industry Index, utilizing a modified equal-weighting scheme. This approach distinguishes XBI from many other sector ETFs that are capitalization-weighted, meaning XBI gives a larger allocation to smaller companies. By equally weighting its holdings, XBI seeks to reduce concentration risk and provide exposure across the market capitalization spectrum. The fund's top holdings include Moderna Inc (2.25%), Roivant Sciences Ltd Ordinary Shares (1.74%), and Vaxcyte Inc Ordinary Shares (1.73%). XBI is designed for investors seeking targeted exposure to the biotechnology industry, allowing them to take strategic or tactical positions within this specific segment. The fund invests almost exclusively in healthcare companies, with a 100% allocation to the sector. XBI may appeal to investors who believe in the growth potential of the biotechnology industry and seek a diversified approach within that sector.

위험 지표

XBI presents several risks inherent to its investment strategy. As a sector-specific ETF with 100% allocation to healthcare, it lacks diversification across different sectors, making it vulnerable to sector-specific downturns or regulatory changes affecting the biotechnology industry. The fund's beta of 1.47 indicates higher volatility compared to the overall market. While the modified equal-weighted index aims to reduce concentration risk, the top 10 holdings still account for a significant portion of the fund's assets. The expense ratio of 0.35% will create a slight drag on performance over time. Country exposure is heavily concentrated in the United States (94.9%), exposing the fund to primarily US-based economic and regulatory risks.

베타: 1.47

운용보수율

0.35%

XBI은(는) 무엇을 보유하고 있나요?

보유 종목	비중
Moderna Inc (MRNA)	2.25%
Roivant Sciences Ltd Ordinary Shares (ROIV)	1.74%
Vaxcyte Inc Ordinary Shares (PCVX)	1.73%
Arcellx Inc (ACLX)	1.66%
Revolution Medicines Inc Ordinary Shares (RVMD)	1.59%
Praxis Precision Medicines Inc Ordinary Shares (PRAX)	1.57%
Amgen Inc (AMGN)	1.50%
Gilead Sciences Inc (GILD)	1.49%
Amicus Therapeutics Inc (FOLD)	1.48%
Mirum Pharmaceuticals Inc (MIRM)	1.41%

보유 종목 및 비중: 2026년 3월 15일 기준. 이 펀드 데이터는 45일 이상 지났습니다. 최신 보유 종목은 발행사에서 확인하세요.

펀드는 어떻게 배분되어 있나요?

섹터	비중
헬스케어	100.0%

국가	비중
미국	94.9%
영국	1.8%
아일랜드	1.4%
스위스	1.1%
네덜란드	0.6%
기타	0.2%

배당수익률

0.35%

iShares Morningstar Small-Cap Growth ETF (JKK) — 0.06% expense ratio
ARK Innovation ETF (ARKK) — 0.75% expense ratio
Invesco QQQ Trust, Series 1 (QQQ) — 0.18% expense ratio
State Street Energy Select Sector SPDR ETF (XLE) — 0.08% expense ratio
WisdomTree Emerging Markets ESG Fund (DVEM) — 0.32% expense ratio
Goldman Sachs ActiveBeta Emerging Markets Equity ETF (GEM) — 0.59% expense ratio
State Street SPDR Dow Jones Industrial Average ETF Trust (DIA) — 0.16% expense ratio
State Street Technology Select Sector SPDR ETF (XLK) — 0.08% expense ratio

State Street Income Allocation ETF (INKM) (Multi-Asset) — 0.50% expense ratio
SPDR S&P 600 Small Cap ETF (SLY) (Equity) — 0.15% expense ratio
State Street SPDR S&P Kensho Future Security ETF (FITE) (Equity) — 0.45% expense ratio

질문 및 답변

What is XBI and what does it track?

XBI, the State Street SPDR S&P Biotech ETF, is an exchange-traded fund that aims to mirror the performance of the S&P Biotechnology Select Industry Index. This index represents the biotechnology sub-industry within the S&P Total Market Index (TMI).

The fund utilizes a modified equal-weighted approach, which differentiates it from capitalization-weighted ETFs.

What is the expense ratio for XBI?

The expense ratio for XBI is 0.35%. This means that for every $10,000 invested in the fund, $35 is used to cover annual operating expenses.

While 0.35% is not the lowest expense ratio available in the equity ETF universe, it is important to consider the specialized exposure XBI offers to the biotechnology sector.

What are the top holdings in XBI?

As of 2026-03-15, the top holdings in XBI are: Moderna Inc (2.25%), Roivant Sciences Ltd Ordinary Shares (1.74%), and Vaxcyte Inc Ordinary Shares (1.73%).

Arcellx Inc (1.66%) and Revolution Medicines Inc Ordinary Shares (1.59%) also rank among the fund's largest positions. These holdings represent a concentrated portion of the fund's overall portfolio, reflecting the specialized nature of the biotechnology sector.

Is XBI a good long-term investment?

Whether XBI is a suitable long-term investment depends on an individual's investment goals, risk tolerance, and outlook on the biotechnology sector. XBI offers targeted exposure to the biotechnology industry, which can be subject to significant volatility.

The fund's beta of 1.47 suggests it is more volatile than the broader market. Past performance does not guarantee future results.

How does XBI compare to similar ETFs?

XBI competes with other biotechnology ETFs, differing primarily in their underlying indexes, weighting methodologies, and expense ratios. XBI's expense ratio is 0.35%.

Some competing ETFs may track different biotechnology indexes or employ market-cap weighting strategies, which could result in different portfolio compositions and performance characteristics. XBI's AUM of $7.79 billion makes it one of the larger biotechnology ETFs available.

Does XBI pay dividends?

Yes, XBI does pay dividends. The current dividend yield for XBI is 0.35%. While this yield is relatively modest compared to some other equity ETFs, it provides a small income component for investors.

The dividend payments are typically distributed quarterly, but this can vary. Investors should note that dividend yields can fluctuate based on market conditions and the dividend policies of the underlying companies held in the ETF.

면책 조항: 이 콘텐츠는 정보 제공만을 목적으로 하며 투자 조언을 구성하지 않습니다. 항상 자체 조사를 수행하고 재정 고문과 상담하십시오.

데이터는 정보 제공만을 목적으로 제공됩니다.

이 페이지는 기계가 작성했으며, 페이지별 사람 검수는 거치지 않았습니다. 편집 관리는 체계 차원에서 이루어집니다: 규칙과 출처를 점검하며, 개별 페이지는 점검하지 않습니다.